The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Major CLL updates from EHA 2019
Patrick Thornton, MD, Beaumont Hospital, Dublin, Ireland, tells us about some of the excellent chronic lymphocytic leukemia (CLL) updates presented at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr Thornton discusses a variety of updates, such as bringing novel agents into the frontline setting and reducing the use of chemotherapy, which tends to have more issues with toxicity. The iLLUMINATE, VISION, MURANO CLL12, CLL14, CLL17, studies are also mentioned (NCT02264574, NCT03226301, NCT02005471, NCT02863718, NCT02242942).
